SARPOGRELATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H31NO6
Molecular Weight	429.506
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1

InChI

InChIKey=FFYNAVGJSYHHFO-UHFFFAOYSA-N

InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)

HIDE SMILES / InChI

Molecular Formula	C24H31NO6
Molecular Weight	429.506
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17438407
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/sarpogrelate.html | https://www.ncbi.nlm.nih.gov/pubmed/10980267 | https://clinicaltrials.gov/ct2/show/NCT01165567 | http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF

Sarpogrelate (brand name Anplag; former developmental code names MCI-9042, LS-187,118) is a drug which acts as an antagonist at the 5HT2A and 5-HT2B receptors. It blocks serotonin-induced platelet aggregation and has applications in the treatment of many diseases including diabetes mellitus, Buerger's disease, Raynaud's disease, coronary artery disease, angina pectoris, and atherosclerosis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8937629	Agonist 2752		8.38 nM [Ki]
Serotonin 2b (5-HT2b) receptor 60 Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17609583	Agonist 2752		6.11 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic arterial occlusion 5 Sources: http://www.e-search.ne.jp/~jpr/PDF/MT02.PDF	Primary		Approved 8583	Anplag Approved Use INDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion
Contrast induced nephropathy 2 Sources: https://clinicaltrials.gov/ct2/show/NCT01165567	Preventing		Phase IV 63	Anplag Approved Use INDICATIONS. Improvement of ischemic symptoms including ulcer, pain and feeling of coldness, associated with chronic arterial occlusion

C_max

Value	Dose	Analyte	Population
0.3636 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.7218 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
565 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
506.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
62.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
49.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
721.4 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
467.3 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
761 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
0.2908 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.5958 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1754 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1358.4 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
361 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
291.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2352.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1927.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1772.7 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.753 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.753 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=23	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	300 mg 1 times / day steady-state, oral dose: 300 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26089136/	100 mg 2 times / day steady-state, oral dose: 100 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.45 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24325365/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	SARPOGRELATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Analyte	Population
5% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/3/400315_3399006C1020_3_160_1F.pdf#page=25	SARPOGRELATE serum	Homo sapiens
96.8% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24167220/	SARPOGRELATE plasma	Homo sapiens
72% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24167220/	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL plasma	Homo sapiens

Doses

Dose	Population	Adverse events
200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/	Other AEs: Elevated liver enzymes, Upper gastrointestinal symptoms... Other AEs: Elevated liver enzymes (3.3%) Upper gastrointestinal symptoms (0.8%) Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/

AEs

AE	Significance	Dose	Population
Upper gastrointestinal symptoms	0.8%	200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/
Elevated liver enzymes	3.3%	200 mg 3 times / day multiple, oral Higher than recommended Dose: 200 mg, 3 times / day Route: oral Route: multiple Dose: 200 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/16886837/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2A6 879 CYP2C8 1057 CYP2E1 1060 CYP1A2 2153 CYP2B6 926 CYP2C19 2057 P-gp 1741 CYP3A5 136 BCRP 910	P-gp 2052 UGT1A4 399 UGT2B4 278 UGT1A9 423 UGT2B7 456

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2A6 911	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2B6 1160	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2C9 2497	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP3A4 2633	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP3A5 201	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	no [IC50 >50 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27695293/	no [Inhibition 10 uM]
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27695293/	no [Inhibition 10 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27695293/	no [Inhibition 10 uM]
P-gp 1932	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27695293/	no [Inhibition 10 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results Page: 54.0	no
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results \| https://pubmed.ncbi.nlm.nih.gov/25268386/ Page: 1.0	yes [IC50 0.195 uM]		yes (co-administration study) Comment: Co-administration increased Metoprolol AUCt by 1.53-fold and Cmax by 1.62-fold Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results \| https://pubmed.ncbi.nlm.nih.gov/25268386/ Page: 1.0
CYP2D6 2546	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/24167220/	yes [IC50 0.201 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results Page: 6.0	yes [IC50 19.4971 uM]

Drug as victim

Target	Modality	Activity	Metabolite
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23704698/	minor [Km 96.3 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/5160#section=Biological-Test-Results Page: 34.0	no
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23704698/	yes [Km 186.6 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23704698/	yes [Km 476.2 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23704698/	yes [Km 564.1 uM]	1-(DIMETHYLAMINO)-3-(2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)-2-PROPANOL 2

PubMed

Title	Date	PubMed
Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.	2010-01	19834330
Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.	2009-09	19700096
Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate.	2009-08	19672037
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.	2009-08	19520981
Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats.	2009-07-01	19318092
Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft.	2009-05	19233592
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.	2009	19557588
Serotonin induces vasoconstriction of smooth muscle cell-rich neointima through 5-hydroxytryptamine2A receptor in rabbit femoral arteries.	2008-07	18435827
Both 5-hydroxytryptamine 5-HT2A and 5-HT1B receptors are involved in the vasoconstrictor response to 5-HT in the human isolated internal thoracic artery.	2008-07	18430065
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial.	2008-06	18388340
Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation.	2008-05-07	17507105
[Coronary artery bypass grafting for simultaneous subacute stent thrombosis after sirolimus-eluting stent implantation].	2008-05	18464477
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.	2008-04	18418427
New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia.	2008-04	18362437
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.	2008-04	18175064
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.	2008-03	18235151
The effects of a 5-HT2A receptor antagonist on blood flow in lumbar disc herniation: application of nucleus pulposus in a canine model.	2008-02	17973126
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.	2008	18751928
Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.	2007-12-20	18088389
Identification of a key amino acid of the human 5-HT(2B) serotonin receptor important for sarpogrelate binding.	2007-07	17609583
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.	2007-04	17438407
Synthesis and 5-HT2A, 5-HT1A and alpha1-binding affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) benzyl oximes.	2007-03	17335104
Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, attenuates neurogenic pain induced by nucleus pulposus in rats.	2007-02-01	17268262
Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.	2007	17622759
Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate.	2007	17575385
Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice.	2006-12-29	17097612
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.	2006-11	17062970
Induction of indefinite survival of fully mismatched cardiac allografts and generation of regulatory cells by sarpogrelate hydrochloride.	2006-10-27	17060854
Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor.	2006-10	17031071
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury.	2006-09-27	16876202
Identification of amino acid residues important for sarpogrelate binding to the human 5-hydroxytryptamine2A serotonin receptor.	2006-09	16974069
Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia.	2006-09	16936435
Site-directed mutagenesis of the serotonin 5-Hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding.	2006-08	16880620
[Effect of sarpogrelate in enteral feeding of patients with gastroesophageal reflux (GER)].	2006-07	16937942
Homology modelling of the serotoninergic 5-HT2c receptor.	2006-06	16918076
Serotonin acts as an up-regulator of acyl-coenzyme A:cholesterol acyltransferase-1 in human monocyte-macrophages.	2006-06	16157345
Livedo racemosa as a cutaneous manifestation of polycythemia vera.	2006-05-20	16709504
Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.	2006-05	16886837
Peripheral 5-HT2A receptor antagonism attenuates primary thermal hyperalgesia and secondary mechanical allodynia after thermal injury in rats.	2006-05	16527395
The 5-hydroxytryptamine2A receptor antagonist sarpogrelate hydrochloride inhibits acute platelet aggregation in injured endothelium.	2006-04-12	16604825
Impaired potency of bone marrow mononuclear cells for inducing therapeutic angiogenesis in obese diabetic rats.	2006-04	16227342
Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report.	2006-02	16432874
A new method for assessment of an anti-5HT(2A) agent, sarpogrelate hydrochloride, on platelet aggregation.	2006-02	16420586
Sarpogrelate hydrochloride, an antagonist of 5-hydroxytryptamine receptor, improves skin flap survival and suppresses thrombus formation in injured microvessels of rabbits.	2006-01	16425124
Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery.	2006-01	16409475
Contribution of the peripheral 5-HT 2A receptor to mechanical hyperalgesia in a rat model of neuropathic pain.	2005-11	16051396
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.	2005-09	16093733
Effects of a 5-HT2A receptor antagonist, sarpogrelate on thermal or inflammatory pain.	2005-05-23	15916757
Protective effects of sarpogrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts.	2005-04	16010979
Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?	2005	17315603

Patents

Sample Use Guides

In Vivo Use Guide

The usual dosage for adult patients is 100 mg of sarpogrelate hydrochloride, administered after meal three times a day. The dosage may be adjusted according to the patient’s age and symptoms.

Route of Administration: Oral

In Vitro Use Guide

Stably expressing cell lines were constructed in HEK293 cells by transfecting with Lipofectamine 2000 reagent and selecting with 0.5 mg/ml G418-containing growth medium. Cells were split into 24-well plates at a density of 105 cells /well and labeled with 3 μCi/ml [3H]myo-inositol in serum-free DMEM for 24 h. Then the cells were washed with the assay medium (20 mM LiCl, 130 mM NaCl, 900 μM NaH2PO4, 5.4 mM KCl, 1.8 mM CaCl2, and 25 mM glucose in 20 mM HEPES, pH 7.4) and incubated with both SARPOGRELATE (10−9 – 10−4 M) at 37°C for 1 h. Cell extracts, in 10 mM formic acid, were applied to a 1-ml AG1-X8 resin (100 – 200 mesh; Assist Co., Tokyo) column before elution by buffer containing 1 M ammonium formate and 0.1 M formic acid. Radioactivity was measured by a liquid scintillation spectrophotometer.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:16:38 GMT 2025` Edited by `admin` on `Mon Mar 31 18:16:38 GMT 2025`
Record UNII	19P708E787
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

4-(1-(2-(3-METHOXYPHENETHYL)PHENOXY)-3-(DIMETHYLAMINO)PROPAN-2-YLOXY)-4-OXOBUTANOIC ACID SARPOGRELATE

Preferred Name

English

SARPOGRELATE

Official Name

English

Sarpogrelate [WHO-DD]

Common Name

English

BUTANEDIOIC ACID, 1-(2-(DIMETHYLAMINO)-1-((2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)METHYL)ETHYL) ESTER

Systematic Name

English

BUTANEDIOIC ACID, MONO(2-(DIMETHYLAMINO)-1-((2-(2-(3-METHOXYPHENYL)ETHYL)PHENOXY)METHYL)ETHYL) ESTER

Common Name

English

sarpogrelate [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1327